SCHEMBL6646565

SCHEMBL6646565

Cc1ccc(C(=O)Nc2ccc(CNC(=O)c3ccccn3)cc2)c(N2CCC(C)CC2)n1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM4 Q14833 2/20 0.51
ALDH1A1 P00352 2/20 0.48
SMN1; SMN2 Q16637 3/20 0.45
KDM4E B2RXH2 1/20 0.45
RCE1 Q9Y256 1/20 0.45
HTT P42858 2/20 0.43
NPC1 O15118 1/20 0.43
MAPT P10636 1/20 0.43
PKM P14618 1/20 0.43
RAB9A P51151 1/20 0.43
KLF5 Q13887 1/20 0.43
KMT2A Q03164 3/20 0.42
TRPV1 Q8NER1 2/20 0.41
SCN10A Q9Y5Y9 1/20 0.41
SLC2A1 P11166 1/20 0.41
KDR P35968 1/20 0.41
HTR1A P08908 1/20 0.41
HTR2A P28223 1/20 0.41
HDAC3 O15379 1/20 0.41
HDAC4 P56524 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6645235 0.85 GRM4 (0.50) GRM4ALDH1A1SMN1; SMN2KDM4EHTT
SCHEMBL6644506 0.82 ALDH1A1 (0.46) GRM4ALDH1A1SMN1; SMN2KDM4ERCE1
SCHEMBL6646415 0.82 NPC1 (0.50) GRM4ALDH1A1SMN1; SMN2KDM4ERCE1
SCHEMBL6644190 0.80 OGA (0.52) GRM4ALDH1A1SMN1; SMN2KDM4ERCE1
SCHEMBL6646638 0.79 ALDH1A1 (0.48) GRM4ALDH1A1SMN1; SMN2KDM4ERCE1
SCHEMBL6648460 0.78 ALDH1A1 (0.46) GRM4ALDH1A1SMN1; SMN2KDM4ERCE1
SCHEMBL6644382 0.78 ALDH1A1 (0.46) GRM4ALDH1A1SMN1; SMN2KDM4ENPC1
SCHEMBL6645742 0.77 ALDH1A1 (0.44) GRM4ALDH1A1SMN1; SMN2KDM4ERCE1
SCHEMBL6647504 0.77 ALDH1A1 (0.46) GRM4ALDH1A1SMN1; SMN2NPC1MAPT
SCHEMBL6647854 0.76 ALDH1A1 (0.44) GRM4ALDH1A1SMN1; SMN2KDM4ERCE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040133008-A1 Amide compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-07-08 US disclosed
WO-2004039795-A2 AMIDE COMPOUNDS FOR THE TREATMENT OF HYPERLIPIDEMIA FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-05-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040133008-A1 Amide compounds APOB, APOL1, LDLR GRM4 2152/4885ALDH1A1 2174/4885SMN1; SMN2 1836/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.